Illumina, Inc. (ILMN)
NASDAQ: ILMN · Real-Time Price · USD
98.08
+0.40 (0.41%)
Sep 5, 2025, 12:30 PM - Market open
Illumina Employees
Illumina had 10,370 employees as of December 31, 2024. The number of employees decreased by 2,020 or -16.30% compared to the previous year.
Employees
10,370
Change (1Y)
-2,020
Growth (1Y)
-16.30%
Revenue / Employee
$413,115
Profits / Employee
$121,215
Market Cap
15.07B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 10,370 | -2,020 | -16.30% |
Dec 31, 2023 | 12,390 | -970 | -7.26% |
Dec 31, 2022 | 13,360 | 1,610 | 13.70% |
Dec 31, 2021 | 11,750 | 2,400 | 25.67% |
Dec 31, 2020 | 9,350 | 1,650 | 21.43% |
Dec 29, 2019 | 7,700 | 400 | 5.48% |
Dec 30, 2018 | 7,300 | 1,100 | 17.74% |
Dec 31, 2017 | 6,200 | 700 | 12.73% |
Dec 31, 2016 | 5,500 | 900 | 19.57% |
Dec 31, 2015 | 4,600 | 900 | 24.32% |
Dec 28, 2014 | 3,700 | 700 | 23.33% |
Dec 29, 2013 | 3,000 | 800 | 36.36% |
Dec 31, 2012 | 2,200 | -200 | -8.33% |
Dec 30, 2012 | 2,400 | 300 | 14.29% |
Dec 31, 2011 | 2,100 | 319 | 17.91% |
Dec 31, 2010 | 1,781 | 245 | 15.95% |
Dec 28, 2008 | 1,536 | 495 | 47.55% |
Dec 30, 2007 | 1,041 | 445 | 74.66% |
Dec 31, 2006 | 596 | 221 | 58.93% |
Dec 31, 2005 | 375 | 97 | 34.89% |
Dec 31, 2004 | 278 | 42 | 17.80% |
Dec 28, 2003 | 236 | 3 | 1.29% |
Dec 29, 2002 | 233 | 54 | 30.17% |
Dec 30, 2001 | 179 | 74 | 70.48% |
Dec 31, 2000 | 105 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ILMN News
- 2 days ago - Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development - PRNewsWire
- 8 days ago - mRNA Biotechs - Long-Term Value Risks Abound - Seeking Alpha
- 4 weeks ago - Illumina: The Stock Is Still Undervalued - Seeking Alpha
- 5 weeks ago - These Analysts Boost Their Forecasts On Illumina Following Upbeat Results - Benzinga
- 5 weeks ago - Illumina, Inc. (ILMN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025 - PRNewsWire
- 5 weeks ago - Illumina enhances flagship assay to accelerate access to comprehensive tumor profiling - PRNewsWire
- 7 weeks ago - Illumina Stock: What Went Wrong And Why It's Best To Stay Away - Benzinga